FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
Otsuka receives FDA approval for Simtriyo, establishing a new drug class for the treatment of ADHD.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The FDA has approved Simtriyo, also known as centanafadine, for the treatment of ADHD in children, adolescents, and adults. Developed by Otsuka, the medication is described as a triple reuptake inhibitor.
Coverage from BioSpace and Fierce Pharma emphasizes the business impact, noting the approval opens a new drug class with a $615M opportunity. The launch is characterized by Fierce Pharma as the company's next major CNS launch.
Future developments involve the commercial rollout of the drug following the approvals reported by Pharmaceutical Executive, FirstWord Pharma, and Psychiatric Times.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 35m ago.
Quick answers
What is Simtriyo?
Simtriyo (centanafadine) is a triple reuptake inhibitor approved by the FDA for ADHD.
Who can take this medication?
The drug is approved for use in children, adolescents, and adults.
What is the projected market opportunity?
According to BioSpace, the approval opens up a $615M opportunity.
Coverage (5)
- FDA Approves Simtriyo Pharmaceutical Executive · 10h ago
- Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 10h ago
- Otsuka’s ADHD approval opens up new drug class with $615M opportunity BioSpace · 10h ago
- FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 10h ago
- FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’ Fierce Pharma · 10h ago
Topics
Related trends
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to reports of the medication being subpotent.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
ADHD looks different in women and poses unique health risks
Recent coverage highlights how ADHD presents uniquely in women, emphasizing the role of hormones and overlooked symptoms.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Compounded GLP-1 drugs creating concern among doctors and FDA
The FDA and medical professionals are raising alarms over the health risks and legality of compounded GLP-1 weight-loss injections.
Cyclospora outbreak has many changing eating habits, CBS News poll finds; mixed and partisan confidence in FDA
A Cyclospora outbreak is shifting consumer eating habits and driving a surge in demand for local produce and home-growing solutions.